FSD Pharma Inc
CNSX:HUGE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
FSD Pharma Inc
Depreciation & Amortization
FSD Pharma Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
FSD Pharma Inc
CNSX:HUGE
|
Depreciation & Amortization
-$4m
|
CAGR 3-Years
-209%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Depreciation & Amortization
-$1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Depreciation & Amortization
-CA$21.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-30%
|
|
|
Cronos Group Inc
TSX:CRON
|
Depreciation & Amortization
-$2.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-37%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Depreciation & Amortization
-CA$49.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-86%
|
|
FSD Pharma Inc
Glance View
FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. The company is headquartered in Toronto, Ontario and currently employs 10 full-time employees. The company went IPO on 2018-05-29. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its lead compound, FSD 201, ultra-micronized Palmitoyl (PEA). FSD 201 stabilizes mast cells of the human body and down-regulate the proinflammatory cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a subsidiary of the Company, has worldwide rights to compounds shown to prevent and reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, the Company is focused on develop a psychoactive (psychedelic-based) therapeutic of neurodegenerative disorders.
See Also
What is FSD Pharma Inc's Depreciation & Amortization?
Depreciation & Amortization
-4m
USD
Based on the financial report for Dec 31, 2021, FSD Pharma Inc's Depreciation & Amortization amounts to -4m USD.
What is FSD Pharma Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
-209%
Over the last year, the Depreciation & Amortization growth was -4%. The average annual Depreciation & Amortization growth rates for FSD Pharma Inc have been -209% over the past three years .
